Company: ARTL
Filing Date: 2025-10-01
Form Type: 424B5
Source: 0001640334-25-001763
Chunk: 1

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-10-01
Form: 424B5
Chunk 1
---
 will the aggregate market value of securities sold by us or on our behalf under this prospectus supplement pursuant to General Instruction I.B.6 of Form S-3 during the twelve-month period immediately prior to, and including, the date of any such sale, exceed one-third of the aggregate market value of our common stock held by non-affiliates. During the twelve-month period that ends on and includes the date hereof, we have sold 790,590 shares of our common stock pursuant to General Instruction I.B.6 of Form S-3, for aggregate gross proceeds of $3,706,347.75.

Investing in our securities involves a high degree of risk. Please read “Risk Factors” beginning on page S-6 of this prospectus supplement, page 9 of the accompanying prospectus, and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a discussion of the factors you should carefully consider before deciding to purchase our securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                  |     | Per Share |       |     | Per Pre-Funded Warrant |       |     | Total(2) |              |
|:---------------------------------|:----|:----------|------:|:----|:-----------------------|------:|:----|:---------|-------------:|
| Offering Price                   |     | $         | 4.400 |     | $                      | 4.399 |     | $        | 1,999,984.67 |
| Underwriting discounts(1)        |     | $         | 0.308 |     | $                      | 0.308 |     | $        |   139,999.86 |
| Proceeds, before expenses, to us |     | $         | 4.092 |     | $                      | 4.091 |     | $        | 1,859,984.81 |

| (1) | We will also pay the underwriter for certain expenses incurred in this offering. See “Underwriting” on page S-15 of this prospectus supplement for more information regarding the underwriting compensation. |
| (2) | Assumes the underwriter does not exercise its over-allotment option.                                                                                                                                         |

We have granted the underwriter an option for a period ending 45